New drug cocktail shows promise for rare cancers

NCT ID NCT05142241

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether a combination of two drugs, talazoparib and temozolomide, can shrink tumors in people with rare cancers that have spread. The study includes 14 participants with advanced rare solid tumors, such as pheochromocytoma or paraganglioma, who have no standard treatment options left. The goal is to see if the drugs can stop the cancer from growing or cause it to shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talazoparib and temozolomide
What this could lead to: If it works, this could offer a new treatment option for people with rare, advanced cancers that have stopped responding to standard therapy.
What could go wrong: This is a very small, early-phase trial (14 participants) with no control group. The combination may not shrink tumors or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL GLAND PHEOCHROMOCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal gland pheochromocytoma cancer hematopoietic and lymphoid system neoplasm paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL GLAND PHEOCHROMOCYTOMA HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM MALIGNANT SOLID NEOPLASM PARAGANGLIOMA

Contacts and locations

Locations

National Cancer Institute Developmental Therapeutics Clinic

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.